Clinical Trial Update: Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma [Phase 1]

View source ↗

Summary

A phase 1 trial evaluating the combination of ipilimumab and nivolumab for stage III/IV unresectable/metastatic cutaneous melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Status: TERMINATED